Aquestive Therapeutics (NASDAQ:AQST) Issues Earnings Results, Misses Expectations By $0.01 EPS

Aquestive Therapeutics (NASDAQ:AQST) posted its earnings results on Monday. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01), Zacks reports. The firm had revenue of $13.54 million during the quarter, compared to analysts’ expectations of $12.69 million. During the same quarter in the previous year, the business earned ($0.03) EPS.

Aquestive Therapeutics Stock Up 6.6 %

NASDAQ:AQST traded up $0.32 on Wednesday, reaching $5.07. 1,948,168 shares of the company’s stock were exchanged, compared to its average volume of 1,755,199. The business has a fifty day moving average of $4.90 and a 200-day moving average of $3.82. Aquestive Therapeutics has a 52-week low of $1.55 and a 52-week high of $6.23. The firm has a market capitalization of $461.67 million, a price-to-earnings ratio of -11.00 and a beta of 2.82.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. JMP Securities reiterated a “market outperform” rating and set a $9.00 target price on shares of Aquestive Therapeutics in a research report on Tuesday, October 8th. Leerink Partners raised their target price on Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an “outperform” rating in a research note on Friday, October 25th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Aquestive Therapeutics in a research report on Wednesday. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $8.83.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.